By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Visterra, Inc. 

One Kendall Square
Suite B3301
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-498-1070 Fax: 617-498-1073


SEARCH JOBS


Industry
Biotechnology






Company News
Visterra, Inc.’s Monoclonal Antibody In Development For The Treatment Of Influenza A, VIS410, Demonstrated Significant Antiviral Activity And Reduced Duration Of Respiratory Symptoms In Phase IIa Challenge Study 10/5/2015 10:31:10 AM
Visterra, Inc. Awarded Contract Valued at Up to $204.5 Million 10/5/2015 8:24:44 AM
Visterra, Inc. And Serum Institute of India, Ltd. Announce Collaboration To Advance VIS513, A Monoclonal Antibody In Development For The Treatment Of Dengue, In The Indian Subcontinent 9/9/2015 11:18:31 AM
Visterra, Inc. Announces Appointment Of John Weidenbruch As General Counsel 9/2/2015 10:51:08 AM
Visterra, Inc. Announces Publication Of Data Demonstrating The Effectiveness Of VIS410 Against Seasonal And Potential Pandemic Influenza Strains 8/18/2015 8:34:08 AM
Visterra, Inc. Announces Publication In The Journal Cell, Demonstrating That Novel Antibody, VIS513, Broadly Neutralizes All Four Serotypes Of Dengue Virus In Preclinical Studies 7/17/2015 9:11:24 AM
Visterra, Inc. Announces Presentation Of Data At International Influenza Meeting On The Efficacy Of VIS410 For Treatment Of A Deadly Strain Of Avian Influenza 6/2/2015 1:28:20 PM
Visterra, Inc. Announces Presentation Of Data At International Influenza Meeting On The Efficacy Of VIS410 For Treatment Of A Deadly Strain Of Avian Influenza 6/2/2015 11:33:00 AM
Visterra, Inc. Partners With A*STAR To Develop VIS513, A Monoclonal Antibody For Dengue 5/22/2015 10:42:49 AM
Visterra, Inc. Announces Additions To Its Management Team And Board Of Directors 10/31/2014 9:21:33 AM
123
//-->